These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 16052093)

  • 1. Progression of renal impairment under therapy with tenofovir.
    Jülg BD; Bogner JR; Crispin A; Goebel FD
    AIDS; 2005 Aug; 19(12):1332-3. PubMed ID: 16052093
    [No Abstract]   [Full Text] [Related]  

  • 2. Tenofovir-associated decline in renal function.
    Crane HM; Kestenbaum B; Harrington RD; Kitahata MM
    J Infect Dis; 2008 Sep; 198(6):937; author reply 937-8. PubMed ID: 18721062
    [No Abstract]   [Full Text] [Related]  

  • 3. Is tenofovir-related renal toxicity incompletely reversible?
    Campbell LJ; Hamzah L; Post FA
    J Acquir Immune Defic Syndr; 2011 Mar; 56(3):e95; author reply e95-6. PubMed ID: 21317581
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of renal adverse effects of combination anti-retroviral therapy including tenofovir in HIV-infected patients.
    Tanaka H; Arai M; Tomoda Y; Wada T; Yago K; Satoh M
    J Pharm Pharm Sci; 2013; 16(3):405-13. PubMed ID: 24021289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction.
    Mauss S; Berger F; Schmutz G
    AIDS; 2005 Jan; 19(1):93-5. PubMed ID: 15627039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a Primary Healthcare Setting in South Africa.
    Kamkuemah M; Kaplan R; Bekker LG; Little F; Myer L
    Trop Med Int Health; 2015 Apr; 20(4):518-26. PubMed ID: 25442109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal toxicity of long-term therapy with tenofovir in HIV-infected patients.
    Monteagudo-Chu MO; Chang MH; Fung HB; Bräu N
    J Pharm Pract; 2012 Oct; 25(5):552-9. PubMed ID: 22551561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Conclusions. Tenofovir].
    Mallolas J
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():62-4. PubMed ID: 19195439
    [No Abstract]   [Full Text] [Related]  

  • 9. Renal function with use of a tenofovir-containing initial antiretroviral regimen.
    Gallant JE; Moore RD
    AIDS; 2009 Sep; 23(15):1971-5. PubMed ID: 19696652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Report from the 13th retrovirus conference. Renal tenofovir debate continues.
    Nagy GS
    AIDS Clin Care; 2006 Apr; 18(4):37-8. PubMed ID: 16718881
    [No Abstract]   [Full Text] [Related]  

  • 11. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF.
    Kinai E; Hanabusa H
    AIDS Res Hum Retroviruses; 2009 Apr; 25(4):387-94. PubMed ID: 19361280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.
    Goicoechea M; Liu S; Best B; Sun S; Jain S; Kemper C; Witt M; Diamond C; Haubrich R; Louie S;
    J Infect Dis; 2008 Jan; 197(1):102-8. PubMed ID: 18171292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement in chronic renal impairment following the discontinuation of tenofovir in two HIV-infected patients.
    Gracey D; Post J; MacLeod C; McKenzie P
    Nephrology (Carlton); 2011 May; 16(4):453-5. PubMed ID: 21518120
    [No Abstract]   [Full Text] [Related]  

  • 14. Tenofovir and changes in renal function.
    Flandre P
    AIDS; 2010 Feb; 24(4):619-20. PubMed ID: 20195075
    [No Abstract]   [Full Text] [Related]  

  • 15. Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naïve patients.
    Calza L; Trapani F; Tedeschi S; Piergentili B; Manfredi R; Colangeli V; Viale P
    Scand J Infect Dis; 2011 Aug; 43(8):656-60. PubMed ID: 21453205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal function in patients with preexisting renal disease receiving tenofovir-containing highly active antiretroviral therapy in the HIV outpatient study.
    Young B; Buchacz K; Moorman A; Wood KC; Brooks JT;
    AIDS Patient Care STDS; 2009 Aug; 23(8):589-92. PubMed ID: 19591609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal safety of tenofovir in HIV treatment-experienced patients.
    Izzedine H; Isnard-Bagnis C; Hulot JS; Vittecoq D; Cheng A; Jais CK; Launay-Vacher V; Deray G
    AIDS; 2004 Apr; 18(7):1074-6. PubMed ID: 15096814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is phosphatemia the best tool to monitor renal tenofovir toxicity?
    Essig M; Duval X; Kaied FA; Iordache L; Gervais A; Longuet P; Blanchet F; Peytavin G; Leport C
    J Acquir Immune Defic Syndr; 2007 Oct; 46(2):256-8. PubMed ID: 17895770
    [No Abstract]   [Full Text] [Related]  

  • 19. Tenofovir and changes in renal function.
    Gupta SK
    Clin Infect Dis; 2005 Aug; 41(4):570-1; author reply 571. PubMed ID: 16028175
    [No Abstract]   [Full Text] [Related]  

  • 20. Determination of kidney function before tenofovir initiation: four-fold difference in need of tenofovir dose reduction depending on method used.
    van Griensven J; Sopheak T; Koole O; Verpooten GA; Lynen L
    J Acquir Immune Defic Syndr; 2011 Jun; 57(2):e21-3. PubMed ID: 21709448
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.